[CH3:1][O:2][C:3](=[O:16])[CH2:4][C:5]1[C:9]2[C:10]([Cl:15])=[CH:11][C:12]([OH:14])=[CH:13][C:8]=2[S:7][CH:6]=1.[CH3:17][N:18]1[C:22]([CH2:23]O)=[CH:21][C:20]([C:25]([F:28])([F:27])[F:26])=[N:19]1.C1CCN(C(N=NC(N2CCCCC2)=O)=O)CC1.C(P(CCCC)CCCC)CCC>C1COCC1>[CH3:1][O:2][C:3](=[O:16])[CH2:4][C:5]1[C:9]2[C:10]([Cl:15])=[CH:11][C:12]([O:14][CH2:23][C:22]3[N:18]([CH3:17])[N:19]=[C:20]([C:25]([F:28])([F:26])[F:27])[CH:21]=3)=[CH:13][C:8]=2[S:7][CH:6]=1To a mixture of methyl(4-chloro-6-hydroxy-1-benzothiophen-3-yl)acetate (750 mg) and THF (dry) (10 mL) were added (1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)methanol (632 mg), ADDP (958 mg) and tri-n-butylphosphine (1.442 mL) at room temperature. The mixture was stirred at room temperature for 16 h. The insoluble material was removed by filtration, and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (EtOAc/hexane). The product was crystallized from EtOAc-hexane to give the title compound (1132 mg).